1 Correction to: Clin Drug Investig (2019) https://doi.org/10.1007/s40261-018-0741-2

An Online First version of this article was made available online at https://rd.springer.com/article/10.1007%2Fs40261-018-0741-2 on 3 January 2019. An error was subsequently identified in the article, and the following correction should be noted:


Correction to Fig. 1 caption


The caption of Fig. 1, which previously read:


“Fig. 1 Inhibition of ER/HER2 cross-talk with neratinib plus endocrine therapy. E oestrogen, ER oestrogen receptor, HR hormone receptor, HER2 human epidermal growth factor receptor 2”


Should read:


“Fig. 1 Inhibition of ER/HER2 cross-talk with neratinib plus endocrine therapy. E oestrogen, ER oestrogen receptor, HR hormone receptor, HER2 human epidermal growth factor receptor 2. © Puma Biotechnology, 2018 (published with permission)”